Steven Yeh, MD, provides a brief overview of available therapies for noninfectious uveitis and uveitis macular edema.
Sheryl Stevenson
Advertisement
Sheryl brings a wealth of editorial experience to MJH Life Sciences’ Eye Care Network, having engaged with the readers and the greater ophthalmic community of Ophthalmology Times for more than 20 years. As Group Editorial Director, Sheryl’s purview extends across the print and digital network of Ophthalmology Times, Ophthalmology Times Europe, Modern Retina and Optometry Times. Prior to ophthalmology, Sheryl previously covered the fields of audiology and confectionery science/technology/manufacturing.
Sheryl is also passionate about the mission, vision and values of Ophthalmic World Leaders (OWL) and recently completed her term on its Board of Directors. She continues to volunteer as Editor-in-Chief of the organization’s EMPOWER Magazine. In 2013, she was honored with the group’s inaugural Rising Star Award.
In addition, she has served as a judge for Crain's Cleveland Business Health Care Heroes Awards program as well as the Jesse H. Neal National Business Journalism Awards.
Articles by Sheryl Stevenson
Though the speed of traditional guillotine cutters has increased significantly in recent years, there are certain limitations. With the advent of hypersonic vitrectomy, Sunir J. Garg, MD, FACS, explains how retinal surgeons can remove the vitreous gel with more efficiency.
In the study, the faricimab molecule, which is a combined anti-Ang2 and anti-VEGF, performed better than the aflibercept drug in many different ways. Rishi P. Singh, MD, FASRS, summarizes some of these key findings.
This new surgical technique offers precision down to the micron level, which is more precise than a surgeon can achieve by themselves.
At Angiogenesis, Dr. SriniVas R. Sadda discusses how choriocapillaris may predict the rate of progression of atrophy.
Dr. Nadia K. Waheed reviews the latest updates on the FOCUS trial, evaluating AAV-based viral vector GT005 for the treatment of geographic atrophy.
Dr. David S. Boyer describes how blocking Connexin-43 may improve the retinal vascular system function in patients with diabetes, potentially creating a future of oral medication for treatment of diabetic retinopathy and AMD.
EyeCon co-chairs Peter J. McDonnell, MD, and Oluwatosin U. Smith, MD, discuss the virtual conference and its relevance to ophthalmologists across the country.
Advertisement
Advertisement
Advertisement
Trending on Modern Retina
1
Navigating geographic atrophy from biomarkers to bilateral therapy
2
Eichenbaum Acorns: Mentorship, momentum, and the making of a retina podcast
3
Ollin Biosciences reports positive head-to-head phase 1b data for OLN324 vs faricimab
4